LEGGE, FRANCESCO
LEGGE, FRANCESCO
Dipartimento di Medicina e Chirurgia
[Biological factors with prognostic significance in ovarian cancer]. Fattori biologici con significato prognostico nel cancro ovarico
2001-01-01 Ferrandina, G; Legge, F; Fagotti, A; Fanfani, F; Mancuso, S; Scambia, G
[Familial ovarian carcinoma]
2001-01-01 Greggi, S; Legge, F; Mancuso, S
A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge
2007-01-01 Ferrandina, G; Legge, F; Mey, V; Nannizzi, S; Ricciardi, S; Petrillo, M; Corrado, G; Scambia, G
A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients
2022-01-01 Loizzi, V; Cicinelli, E; Del Vecchio, V; Arezzo, F; Deromemaj, X; Kardhashi, A; Paradiso, A; Legge, F; Natalicchio, Mi; Resta, L; Resta, N; Loconte, Dc; Cormio, G
Adjuvant volumetric-modulated arc therapy with simultaneous integrated boost in endometrial cancer. Planning and toxicity comparison
2014-01-01 Macchia, G; Cilla, S; Morganti, Ag; Deodato, F; Legge, F; Piermattei, A; Chiantera, V; Scambia, G; Valentini, V; Ferrandina, G
Advances in surgical management of cervical cancer
2009-01-01 Ercoli, A; Iannone, V; Legge, F; Fagotti, A; Fanfani, F; Carone, V; D'Asta, M; Scambia, G; Ferrandina, G
Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinicopathological parameters
2004-01-01 Fagotti, A; Ferrandina, G; Fanfani, F; Legge, F; Lauriola, L; Gessi, M; Castelli, P; Barbieri, F; Minelli, L; Scambia, G
Analysis of survivin expression in ovarian cancer and its correlation with clinical, surgical, pathological and apoptosis-related parameters
2004-01-01 Ferrandina, G; Legge, F; Martinelli, E; Gessi, M; Gallotta, V; Salutari, V; Zannoni, Gf; Ranelletti, Fo; Scambia, G
Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study
2022-01-01 Restaino, S; Buda, A; Puppo, A; Capozzi, Va; Sozzi, G; Casarin, J; Gallitelli, V; Murgia, F; Vizzielli, G; Baroni, A; Corrado, G; Pasciuto, T; Ferrari, D; Novelli, A; Berretta, R; Legge, F; Vizza, E; Chiantera, V; Ghezzi, F; Landoni, F; Scambia, G; Fanfani, F
Angiogenesis inhibitors in gynecological cancers
2003-01-01 Ferrandina, G; Legge, F; Gallotta, V; Salutari, V; Scambia, G
Biologia e genetica molecolare in ginecologia ed ostetricia
2007-01-01 Legge, F; Ferrandina, G; Paglia, A; Scambia, G
Biologia e genetica molecolare in ginecologia ed ostetricia
2013-01-01 Legge, F; Ferrandina, G; Paglia, A; Scambia, G; Legge, F; Ferrandina, G; Paglia, A; Scambia, G
Biological characterization of ovarian cancer: prognostic and therapeutic implications
2005-01-01 Legge, F; Ferrandina, G; Salutari, V; Scambia, G
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease
2002-01-01 Ceccaroni, M; Genuardi, M; Legge, F; Lucci-Cordisco, E; Carrara, S; D'Amico, F; Greggi, S; Scambia, G
Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III
2011-01-01 Pignata, S; Scambia, G; Ferrandina, G; Savarese, A; Sorio, R; Breda, F; Gebbia, V; Musso, P; Frigerio, L; Del Medico, P; Lombardi, Av; Febbraio, A; Scollo, P; Ferro, A; Tamberi, S; Brandes, A; Ravaioli, A; Valerio, Mr; Aitini, E; Natale, D; Scaltriti, L; Greggi, S; Pisano, C; Lorusso, D; Salutari, V; Legge, F; Di Maio, M; Morabito, A; Gallo, C; Perrone, F
Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial
2010-01-01 Pignata, S; Scambia, G; Savarese, A; Sorio, R; Breda, E; Legge, F; Gebbia, V; Musso, P; Gallo, C; Perrone, F on behalf of MITO group
Celecoxib modulates angiogenesis-related parameters in both sera and tumor biopsies from cervical cancer patients
2005-01-01 Legge, F; Ranelletti, Fo; Zannoni, Gf; Martinelli, E; Gessi, M; Salutari, V; Gallotta, V; Lorusso, D; Scambia, G; Ferrandina, G
Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: A pilot study
2003-01-01 Ferrandina, G; Ranelletti, Fo; Legge, F; Lauriola, L; Salutari, V; Gessi, M; Testa, Ac; Werner, U; Navarra, P; Tringali, G; Battaglia, A; Scambia, G
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study
2003-01-01 Ferrandina, G; Ranelletti, Fo; Legge, F; Lauriola, L; Salutari, V; Gessi, M; Testa, Ac; Werner, U; Navarra, P; Tringali, G; Battaglia, A; Pozzo, C; Scambia, G
Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a phase II study
2005-01-01 Ferrandina, G; Legge, F; Gallotta, V; Lorusso, D; Testa, Ac; Salutari, V; Paglia, A; Col angelo, M; Fulfaro, F; Scambia, G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| [Biological factors with prognostic significance in ovarian cancer]. Fattori biologici con significato prognostico nel cancro ovarico | 1-gen-2001 | Ferrandina, G; Legge, F; Fagotti, A; Fanfani, F; Mancuso, S; Scambia, G | |
| [Familial ovarian carcinoma] | 1-gen-2001 | Greggi, S; Legge, F; Mancuso, S | |
| A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge | 1-gen-2007 | Ferrandina, G; Legge, F; Mey, V; Nannizzi, S; Ricciardi, S; Petrillo, M; Corrado, G; Scambia, G | |
| A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients | 1-gen-2022 | Loizzi, V; Cicinelli, E; Del Vecchio, V; Arezzo, F; Deromemaj, X; Kardhashi, A; Paradiso, A; Legge, F; Natalicchio, Mi; Resta, L; Resta, N; Loconte, Dc; Cormio, G | |
| Adjuvant volumetric-modulated arc therapy with simultaneous integrated boost in endometrial cancer. Planning and toxicity comparison | 1-gen-2014 | Macchia, G; Cilla, S; Morganti, Ag; Deodato, F; Legge, F; Piermattei, A; Chiantera, V; Scambia, G; Valentini, V; Ferrandina, G | |
| Advances in surgical management of cervical cancer | 1-gen-2009 | Ercoli, A; Iannone, V; Legge, F; Fagotti, A; Fanfani, F; Carone, V; D'Asta, M; Scambia, G; Ferrandina, G | |
| Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinicopathological parameters | 1-gen-2004 | Fagotti, A; Ferrandina, G; Fanfani, F; Legge, F; Lauriola, L; Gessi, M; Castelli, P; Barbieri, F; Minelli, L; Scambia, G | |
| Analysis of survivin expression in ovarian cancer and its correlation with clinical, surgical, pathological and apoptosis-related parameters | 1-gen-2004 | Ferrandina, G; Legge, F; Martinelli, E; Gessi, M; Gallotta, V; Salutari, V; Zannoni, Gf; Ranelletti, Fo; Scambia, G | |
| Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study | 1-gen-2022 | Restaino, S; Buda, A; Puppo, A; Capozzi, Va; Sozzi, G; Casarin, J; Gallitelli, V; Murgia, F; Vizzielli, G; Baroni, A; Corrado, G; Pasciuto, T; Ferrari, D; Novelli, A; Berretta, R; Legge, F; Vizza, E; Chiantera, V; Ghezzi, F; Landoni, F; Scambia, G; Fanfani, F | |
| Angiogenesis inhibitors in gynecological cancers | 1-gen-2003 | Ferrandina, G; Legge, F; Gallotta, V; Salutari, V; Scambia, G | |
| Biologia e genetica molecolare in ginecologia ed ostetricia | 1-gen-2007 | Legge, F; Ferrandina, G; Paglia, A; Scambia, G | |
| Biologia e genetica molecolare in ginecologia ed ostetricia | 1-gen-2013 | Legge, F; Ferrandina, G; Paglia, A; Scambia, G; Legge, F; Ferrandina, G; Paglia, A; Scambia, G | |
| Biological characterization of ovarian cancer: prognostic and therapeutic implications | 1-gen-2005 | Legge, F; Ferrandina, G; Salutari, V; Scambia, G | |
| BRCA1-related malignancies in a family presenting with von Recklinghausen's disease | 1-gen-2002 | Ceccaroni, M; Genuardi, M; Legge, F; Lucci-Cordisco, E; Carrara, S; D'Amico, F; Greggi, S; Scambia, G | |
| Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III | 1-gen-2011 | Pignata, S; Scambia, G; Ferrandina, G; Savarese, A; Sorio, R; Breda, F; Gebbia, V; Musso, P; Frigerio, L; Del Medico, P; Lombardi, Av; Febbraio, A; Scollo, P; Ferro, A; Tamberi, S; Brandes, A; Ravaioli, A; Valerio, Mr; Aitini, E; Natale, D; Scaltriti, L; Greggi, S; Pisano, C; Lorusso, D; Salutari, V; Legge, F; Di Maio, M; Morabito, A; Gallo, C; Perrone, F | |
| Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial | 1-gen-2010 | Pignata, S; Scambia, G; Savarese, A; Sorio, R; Breda, E; Legge, F; Gebbia, V; Musso, P; Gallo, C; Perrone, F on behalf of MITO group | |
| Celecoxib modulates angiogenesis-related parameters in both sera and tumor biopsies from cervical cancer patients | 1-gen-2005 | Legge, F; Ranelletti, Fo; Zannoni, Gf; Martinelli, E; Gessi, M; Salutari, V; Gallotta, V; Lorusso, D; Scambia, G; Ferrandina, G | |
| Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: A pilot study | 1-gen-2003 | Ferrandina, G; Ranelletti, Fo; Legge, F; Lauriola, L; Salutari, V; Gessi, M; Testa, Ac; Werner, U; Navarra, P; Tringali, G; Battaglia, A; Scambia, G | |
| Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study | 1-gen-2003 | Ferrandina, G; Ranelletti, Fo; Legge, F; Lauriola, L; Salutari, V; Gessi, M; Testa, Ac; Werner, U; Navarra, P; Tringali, G; Battaglia, A; Pozzo, C; Scambia, G | |
| Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a phase II study | 1-gen-2005 | Ferrandina, G; Legge, F; Gallotta, V; Lorusso, D; Testa, Ac; Salutari, V; Paglia, A; Col angelo, M; Fulfaro, F; Scambia, G |